S/D

(redirected from Solvent/Detergent)
AcronymDefinition
S/DShutdown
S/DSource/Drain
S/DSystem Description
S/DSame Difference
S/DSystolic/Diastolic
S/DSight Draft
S/DSocial Drinker
S/DSynchro-To-Digital
S/DShifta/Deband (gaming)
S/DSolvent/Detergent
References in periodicals archive ?
Solvent/detergent plasma: pharmaceutical characteristics and clinical experience.
Kogenate(R) FS/KOGENATE(R) Bayer does not use albumin in its purification or formulation and includes a solvent/detergent viral inactivation step, thereby further reducing the potential risk of viral transmission.
As part of the most recent initiatives, shrink- bands have been added to Plasbumin(R), Albumin (Human); and Bayer BP's hyperimmunes in vials, including BayHep B(R), Hepatitis B Immune Globulin (Human) Solvent/Detergent Treated; BayRab(R), Rabies Immune Globulin (Human) Solvent/Detergent Treated; and BayGam(R), Immune Globulin (Human) Solvent/Detergent Treated.
Kogenate(R) FS/KOGENATE(R) Bayer does not use albumin in its purification or formulation, and includes a solvent/detergent viral inactivation step, thereby further reducing the potential risk of viral transmission.
Solvent/detergent treatment -- Pasteurization, or heat treatment -- Extraction using acetone -- Incubation in acidic solutions -- A new viral inactivation technology utilizing caprylate
Kogenate(R) FS does not use albumin in its purification or formulation, and includes a solvent/detergent viral inactivation step, thereby further reducing potential risk of viral transmission.
Viral inactivation processes used in the manufacture of Bayer BP's life-saving and life-enhancing processes include pasteurization (heat treatment), solvent/detergent treatment, extraction using acetone, incubation in acidic solutions, and the new caprylate technology to be used in the manufacture of Gamunex(R), once that product receives final approval.
This product utilises additional safety enhancements such as a solvent/detergent viral activation step and no albumin added to final formulation.
Food and Drug Administration (FDA) to market OCTAGAM(R), Immune Globulin Intravenous (Human) 5%, a liquid, ready-to-use, solvent/detergent treated immunoglobulin intravenous (IGIV) product that has been a market leader in Europe for more than 10 years, the company announced today.
This product utilizes additional safety enhancements such as a solvent/detergent viral activation step and no albumin added to final formulation.
ZLB Bioplasma's Carimune(TM) NF is the only IGIV product offered in the United States to employ nanofiltration, a process which targets both enveloped and non-enveloped viruses, as well as other particles larger than 50 nanometers -- all without using heat or chemicals such as solvent/detergent and caprylate.
WinRho SD is manufactured using solvent/detergent (SD) viral inactivation step that provides an added level of safety through inactivation of lipid enveloped viruses such as hepatitis B, hepatitis C and HIV.